Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Equity Ratio (2016 - 2025)

Cytosorbents (CTSO) has disclosed Equity Ratio for 14 consecutive years, with 0.2 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 29.58% year-over-year to 0.2, compared with a TTM value of 0.2 through Sep 2025, down 29.58%, and an annual FY2024 reading of 0.23, down 46.82% over the prior year.
  • Equity Ratio was 0.2 for Q3 2025 at Cytosorbents, down from 0.24 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.88 in Q1 2021 and bottomed at 0.2 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.51, with a median of 0.49 recorded in 2023.
  • The sharpest move saw Equity Ratio surged 83.26% in 2021, then plummeted 46.82% in 2024.
  • Year by year, Equity Ratio stood at 0.7 in 2021, then fell by 19.97% to 0.56 in 2022, then dropped by 21.2% to 0.44 in 2023, then tumbled by 46.82% to 0.23 in 2024, then fell by 15.91% to 0.2 in 2025.
  • Business Quant data shows Equity Ratio for CTSO at 0.2 in Q3 2025, 0.24 in Q2 2025, and 0.23 in Q4 2024.